GT
HARP

Glenmede Trust’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Glenmede Trust’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-9
Closed -$1K – 2401
2020
Q3 		$1K Sell
9
-1
-10% -$144 ﹤0.01% 2423
2020
Q2 		$1K Buy
+10
New +$1.56K ﹤0.01% 2402

Other funds holding HARP

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Glenmede Trust's HARP Position: Q4 2020 in Review

Glenmede Trust sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q4 2020, closing a stake of 9 shares — an estimated $1K sold.

Glenmede Trust first reported a position in HARP in Q2 2020 and held it in 2 quarters. The position peaked at $1K in Q3 2020. 77 funds tracked by Wall St. Rank hold HARP as of Q4 2020.

  • Glenmede Trust reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 9 Harpoon Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $1K.
  • Glenmede Trust first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • Glenmede Trust's Harpoon Therapeutics, Inc. Common Stock position peaked at $1K in Q3 2020.
  • 77 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.